Monday's Health Winners & Losers

03/26/07 - 01:29 PM EDT

Robert Holmes

Abbott Laboratories (ABT Quote) was one of Monday's winners, a day after the company reported positive results from a clinical trial of its Xience drug-coated stent, clearing an important hurdle on the path to Food and Drug Administration approval. Abbott was recently adding $2.07, or 3.8%, to $55.93.

Meanwhile, shares of Boston Scientific (BSX Quote) slid more than 5% after the performance of Abbott's Xience stent was deemed superior to that of Boston Scientific's Taxus stent in a study. Lately, the stock was off 77 cents, or 5.1%, to $14.45.

Osiris Therapeutics (OSIR Quote) jumped after the company reported positive safety and efficacy data on Sunday from a phase I study of its adult stem-cell therapy, Provacel, in patients with heart disease. Osiris was higher by $2, or 11.2%, at $19.90.

Shares of Merck (MRK Quote) were easing after the company announced a joint venture with Schering-Plough (SGP Quote) that will combine the cholesterol drug Lipitor with Zetia. Merck was losing 28 cents, or 0.6%, to $44.17.

Meanwhile, Schering-Plough was adding 52 cents, or 2.1%, to $25.14. Pfizer (PFE Quote), which holds the patent for Lipitor until 2010, was recently down 16 cents, or 0.6%, to $25.50.

Elsewhere, Biosite (BSTE Quote) soared 51.3% after Beckman Coulter (BEC Quote) said it will acquire the company. Alexion Pharmaceuticals (ALXN Quote) was rising 10.6% to $44.30.

Among decliners, CV Therapeutics (CVTX Quote) dropped 20% to $6.86 on a downgrade by Deutsche Securities. Express Scripts (MDT Quote) was sliding 1.8% to $82.16. Medtronic (MDT Quote) was down 1.3% to $49.26.

Your Recent Quotes: Quote Up0 | Quote Down0
 
Dow S&P 500 NASDAQ
Oil*
65.43
8,280.74
896.42
1,796.52
10 Yr
3.50%
223.32
26.91
49.20
-2.63%
-2.91%
-2.67%
Data delayed 20 min
Get Jim Cramer's Free Newsletter

The Daily Booyah!
Get your daily dose of Cramer in your inbox.
Submit
We respect your privacy.

Premium Stock Ideas
Access Action Alerts Plus to find out Cramer's latest picks now!

Brokerage Partners